| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $17,644,518 ) (Continued on the next page) |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01DA055630 | Early Adversity and Drug Use Vulnerability Among Low Income Rural Children: Testing a Neuro-ecological Model of Resilience | 002 | 3 | NIH | 4/9/2025 | $68,369 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R35GM128620 | Biosensor-driven Platforms for Biosynthesis of Natural Products in Bacteria | 001 | 7 | NIH | 11/20/2024 | $353,810 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R35GM148433 | O-glycosylation of cysteine-rich modules | 001 | 3 | NIH | 11/19/2024 | $394,110 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01AI162989 | Targeted Pan-Antifungal Liposomes | 000 | 4 | NIH | 1/18/2025 | $516,754 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01DA055630 | Early Adversity and Drug Use Vulnerability Among Low Income Rural Children: Testing a Neuro-ecological Model of Resilience | 000 | 3 | NIH | 1/17/2025 | $615,311 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R35GM157138 | Characterizing the regulation of cell envelope biosynthesis in Pseudomonas aeruginosa | 000 | 1 | NIH | 12/31/2024 | $361,297 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | D43TW012481 | Digital Mobile Technologies to study Tuberculosis: A Multi-disciplinary Program | 001 | 3 | NIH | 12/29/2024 | $190,876 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | D43TW012481 | Digital Mobile Technologies to study Tuberculosis: A Multi-disciplinary Program | 001 | 3 | NIH | 12/29/2024 | $50,000 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | F31DK141239 | A process evaluation of a pragmatic randomized controlled trial to promote mental health among adults with Type 1 diabetes | 001 | 1 | NIH | 12/5/2024 | $0 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R35GM152057 | Regulation of protein transport in cilia | 001 | 2 | NIH | 11/13/2024 | $490,327 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01AI158743 | Synthetic multi-component influenza vaccines to elicit broad immunity | 000 | 2 | NIH | 11/1/2024 | $660,492 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01AI173144 | Impacts of host lipid composition on antimicrobial susceptibilities of Staphylococcus aureus | 000 | 3 | NIH | 11/4/2024 | $471,568 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01ES034196 | Role of Prokineticin 2 in Metal Neurotoxicity | 000 | 3 | NIH | 10/29/2024 | $339,750 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R61AI187112 | Establishing strains and conditions for long-term P. vivax cultures | 000 | 1 | NIH | 12/6/2024 | $392,710 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01HL173931 | Metabolic control of human endothelial development via the COUP-TF/1-deoxysphingosine axis | 000 | 2 | NIH | 3/28/2025 | $511,305 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01NS119610 | Elucidating the role of NK cells in Lewy body diseases | 000 | 5 | NIH | 3/28/2025 | $334,144 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | DP2AI154416 | Tapeworm stem cells as drivers of regeneration and reproduction | 000 | 5 | NIH | 2/12/2025 | $453,000 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01GM111939 | Structure and Function in alpha-Dystroglycan Glycosylation | 000 | 11 | NIH | 1/8/2025 | $339,923 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R21AI182884 | Maternal vaccination impacts on neonatal susceptibility and response to Bordetella pertussis | 000 | 1 | NIH | 11/13/2024 | $212,265 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01AI174600 | Divergent Calcium Channels of the Apicomplexan parasite Toxoplasma gondii | 000 | 3 | NIH | 1/10/2025 | $582,006 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01ES033892 | Microglial Hv1 Proton Channel as a Mediator of Environmentally-Induced Neuroinflammation and Neurodegeneration | 000 | 4 | NIH | 2/13/2025 | $606,576 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R21AI183057 | The cystic fibrosis sputum compromises the ability of neutrophils to kill Staphylococcus aureus | 000 | 2 | NIH | 2/12/2025 | $217,125 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01ES036241 | Novel Epitranscriptomic Mechanisms in Metal Neurotoxicity | 000 | 1 | NIH | 11/14/2024 | $441,529 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01AG076625 | Implications of Metabolic Dysfunction during Thiamine Insufficiency | 000 | 3 | NIH | 11/14/2024 | $331,600 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R35GM153272 | Indole Alkaloids and Halogenated Phenazines: Platforms for Discovery | 000 | 3 | NIH | 1/6/2025 | $331,600 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | F31DK141239 | A process evaluation of a pragmatic randomized controlled trial to promote mental health among adults with Type 1 diabetes | 002 | 1 | NIH | 12/23/2024 | $3,142 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01AI176776 | Synthesis and transport of outer membrane components across the Gram-negative cell envelope | 000 | 3 | NIH | 12/23/2024 | $640,850 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01AT012783 | Multi-omics approaches to lower the barriers to sustainable production of plant natural products with relevance to human health | 000 | 2 | NIH | 12/6/2024 | $485,272 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R21AI175925 | Development of ganglioside specific IgGs for the treatment of Guillian-Barré Syndrome | 000 | 2 | NIH | 12/6/2024 | $182,243 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | K01DA059329 | Trauma-informed, resilience-based telehealth intervention for improving HIV prevention and HCV care for persons who inject drugs in the Deep South | 001 | 2 | NIH | 1/15/2025 | $188,417 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R35GM149230 | Mechanism and Inhibition of Histone Modifications | 001 | 3 | NIH | 1/13/2025 | $335,675 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01NS119517 | Novel Modulators of TGFß1 signaling in regulation of remyelination by neural stem cells | 000 | 4 | NIH | 11/25/2024 | $335,675 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | F31DK141239 | A process evaluation of a pragmatic randomized controlled trial to promote mental health among adults with Type 1 diabetes | 000 | 1 | NIH | 12/5/2024 | $40,686 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01AI150098 | The Cell Envelope of the Multi-Drug Resistant Pathogen Acinetobacter baumannii | 000 | 6 | NIH | 12/4/2024 | $576,282 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R21NS135412 | Characterizing and treating peripheral nervous system dysfunction in Sanfilippo Syndrome | 000 | 1 | NIH | 1/27/2025 | $226,500 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01HL172496 | Nitric Oxide Functionalized Antibiotics to Combat Infections and Thrombosis for Extracorporeal Life Support | 000 | 2 | NIH | 1/28/2025 | $440,366 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01NS114567 | Precision Medicine for the Peripheral Nervous System Disorder Familiar Dysautonomia | 000 | 5 | NIH | 11/27/2024 | $339,750 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01HD110099 | The Role of the O-GlcNAc Modification in X-linked Intellectual Disability | 000 | 3 | NIH | 1/22/2025 | $333,642 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01DA055630 | Early Adversity and Drug Use Vulnerability Among Low Income Rural Children: Testing a Neuro-ecological Model of Resilience | 001 | 3 | NIH | 1/22/2025 | $54,644 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | F31HD108843 | Utilizing Causal X-Linked Intellectual Disability Variants to Gain Insight into the O-GlcNAc Transferase Enzyme | 000 | 3 | NIH | 12/17/2024 | $48,974 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R21HL168507 | A deep learning-enhanced multiphysics and multiscale framework for predictive modeling of inflammation-induced thrombosis | 000 | 2 | NIH | 4/21/2025 | $171,215 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R21AI182993 | Assessing the Mycobacterium tuberculosis carriage state | 000 | 1 | NIH | 4/21/2025 | $187,998 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01AG074216 | APOE4 effects on glia-neuron interaction in the olfactory bulb | 000 | 3 | NIH | 3/7/2025 | $405,192 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01CA252713 | Canine MHC-I genotyping and tumor specific neoantigen determination | 000 | 5 | NIH | 4/25/2025 | $413,651 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R35GM148240 | Platform for in vivo Metabolism | 001 | 3 | NIH | 3/24/2025 | $368,242 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01AI185090 | Optimization of UltraPCR for detection of and assessment of treatment outcomes in Trypanosoma cruzi infection | 000 | 1 | NIH | 2/28/2025 | $504,703 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R35GM130399 | Analysis of the Metabolic Capabilities of Prokaryotic Cells | 003 | 7 | NIH | 4/7/2025 | $708,492 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R35GM139656 | Unlocking sequence-structure-function-disease relationships in large protein super-families | 001 | 5 | NIH | 3/4/2025 | $415,854 |
| | 2025 | 2025 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 310 E CAMPUS RD RM 409 | ATHENS | GA | 30602-1589 | CLARKE | USA | R01NS128005 | Synaptic Dysfunction and Energy Failure in Parkinson's Disease | 000 | 4 | NIH | 4/8/2025 | $424,679 |
|
